Atrial Fibrillation Trial To Eliminate Risk-factors (AFTTER)

The goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. The main questions it aims to answer are:

1. to understand the baseline characteristics and to explore the occult risk factors of the patients with AF;
2. to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with AF.

Participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

Study Overview

• Status: Completed
• Conditions: Atrial Fibrillation
• Intervention / Treatment: Other: Integrated care

Detailed Description

Atrial fibrillation (AF) is a heart condition that potentially leads to heart failure and ischemic stroke. The prevalence of AF is increasing due to aging population and improved treatment in other cardiovascular field. This study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

• Study Type: Observational
• Enrollment (Actual): 343

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan, 100
    • National Taiwan University Hospita

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with documented atrial fibrillation, either paroxysmal, persistent, or permanent.

Description

Inclusion Criteria:

• At least 18 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram

Exclusion Criteria:

1. Unable to complete the initial assessment and cooperate with the tracker
2. Those who refuse to sign the subject's consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AF burden	The duration in AF on 14-day ECG monitor (percent)	0~24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MACE, major adverse cardiovascular event	ischemic heart disease with acute coronary syndrome, stroke (either ischemic or hemorrhagic stroke), cardiovascular death, and all-cause death	0~24 months

Collaborators and Investigators

• Sponsor: National Taiwan University Hospital
• Investigators: Principal Investigator: Chih-Chieh Yu, MD.PhD, National Taiwan University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2020
• Primary Completion (Actual): August 5, 2024
• Study Completion (Actual): August 31, 2024

Study Registration Dates

• First Submitted: January 30, 2023
• First Submitted That Met QC Criteria: January 30, 2023
• First Posted (Actual): February 8, 2023

Study Record Updates

• Last Update Posted (Estimated): January 16, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Atrial Fibrillation
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Pathological Conditions, Signs and Symptoms; Atrial Fibrillation; Health Services Administration; Delivery of Health Care; Health Care Quality, Access, and Evaluation; Patient Care Management; Delivery of Health Care, Integrated
• Other Study ID Numbers: 202003090RINA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No